Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 73.8%

Neg 0% Neu 0% Pos 73.8%

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.